Imnovid 4 mg (Pomalidomide) Buy Hard Capsules

Imnovid 4 mg Hard Capsules, containing the active ingredient Pomalidomide, is an advanced oral immunomodulatory agent manufactured by Bristol Myers Squibb. It is primarily indicated for the treatment of relapsed and refractory multiple myeloma (RRMM) in patients who have previously received at least two prior therapies, including lenalidomide and bortezomib, and have shown disease progression. This innovative therapy is recognized globally for its potent anti-cancer properties and its role in enhancing immune response while inhibiting myeloma cell proliferation.

Key Features and Benefits:

• Active Ingredient: Pomalidomide – 4 mg per hard capsule.
• Pack Size: 21 hard capsules per box.
• Manufacturer: Bristol Myers Squibb – A globally trusted pharmaceutical leader.
• Indications:
  • Relapsed and Refractory Multiple Myeloma (RRMM): Used in combination with dexamethasone in adult patients.
  • Effective for patients who have become resistant to prior therapies.
• Mechanism of Action:
  Pomalidomide is a thalidomide analogue that exhibits immunomodulatory, anti-angiogenic, and anti-proliferative properties. It:
  • Enhances the activation of T cells and NK cells.
  • Inhibits the growth and survival of multiple myeloma cells.
  • Disrupts cytokine release and tumor microenvironment support.
• Proven Clinical Efficacy:
  • Demonstrated extended progression-free survival (PFS) in patients with heavily pretreated multiple myeloma.
  • Improves overall response rates (ORR) when used in combination with dexamethasone.
  • Provides better disease control in patients resistant to lenalidomide and bortezomib.
• Oral Convenience:
  • Simple once-daily oral dosing.
  • Suitable for outpatient treatment plans.

How Does Imnovid (Pomalidomide) Work?

Imnovid acts on multiple pathways to combat multiple myeloma:

• It modulates the immune system, increasing the killing activity of immune cells like T cells and natural killer (NK) cells.
• It disrupts blood supply (angiogenesis) to the tumor.
• It inhibits the production of pro-inflammatory cytokines (e.g., TNF-alpha, IL-6) that support cancer cell survival.
• Induces apoptosis (programmed cell death) in malignant plasma cells.

Dosage and Administration:

• Recommended Dose:
  • 4 mg once daily, orally, on Days 1 to 21 of each 28-day cycle, in combination with dexamethasone.
• Administration Instructions:
  • Take with or without food.
  • Swallow the capsule whole; do not break, open, or chew.
  • Missed Dose: Skip the missed dose if it is less than 12 hours until the next dose.

Safety Information and Precautions:

• Fetal Risk (Teratogenicity):
  • Pomalidomide is highly teratogenic (like thalidomide). It can cause severe birth defects.
  • Pregnancy Prevention Program is mandatory:
    • Women of childbearing potential must use two reliable contraceptive methods.
    • Men must use condoms if their partner is pregnant or capable of becoming pregnant.
• Thromboembolism Risk:
  • Deep vein thrombosis (DVT) and pulmonary embolism (PE) are potential risks.
  • Prophylactic anticoagulation (e.g., aspirin, low-molecular-weight heparin) is often advised.
• Hematologic Toxicity:
  • Risk of neutropenia, anemia, and thrombocytopenia.
  • Regular blood tests are required during treatment.
• Infections:
  • Increased risk of bacterial, viral, and fungal infections.
  • Prophylactic antibiotics or antivirals may be needed.
• Peripheral Neuropathy:
  • Although less common than thalidomide, mild to moderate neuropathy can occur.

Special Warnings:

• Avoid Blood Donation:
  • Patients must not donate blood during and for 1 month after treatment.
• Male Fertility:
  • Potential impact on male fertility; sperm banking may be considered before starting treatment.
• Smoking:
  • Smoking may reduce Pomalidomide effectiveness.

Why Choose Imnovid (Pomalidomide) 4 mg?

• Proven in Heavily Pretreated Multiple Myeloma:
  • Offers a valuable option for patients resistant to standard therapies.
• Immunomodulatory Agent (IMiD):
  • Part of the highly effective IMiD class of drugs, targeting both the tumor and its microenvironment.
• Oral Treatment:
  • Convenient dosing – Once daily oral regimen improves patient compliance.
• Combination Therapy:
  • Combining with dexamethasone enhances anti-myeloma activity.

Storage Instructions:

• Store at room temperature (below 25°C).
• Keep the capsules in original packaging to protect from moisture.
• Keep out of reach of children.

Who Can Benefit from Imnovid?

• Adult patients diagnosed with relapsed and refractory multiple myeloma (RRMM).
• Individuals who did not respond or progressed on therapies like lenalidomide and bortezomib.

Manufacturer Information:

• Brand: Imnovid 4 mg Hard Capsules.
• Active Substance: Pomalidomide.
• Presentation: 21 Hard Capsules per Box.
• Manufacturer: Bristol Myers Squibb.

Ordering Imnovid 4 mg Online:

Secure your supply of Imnovid (Pomalidomide) 4 mg Capsules through our trusted online platform, ensuring fast delivery, verified authenticity, and competitive pricing.
Our services guarantee global shipping with dedicated customer support.